Evaxion(EVAX) - 2022 Q2 - Quarterly Report

Product Development - Evaxion Biotech A/S announced the introduction of its second bacterial product candidate[6] - The press release serves as a key communication tool for stakeholders regarding product development[6] - The company is focused on advancing its biotechnology initiatives in the market[6] Regulatory Compliance - The report is filed under Form 6-K, complying with the Securities Exchange Act of 1934[1] - The filing includes a check mark indicating the submission of Form 20-F[2] - The report is part of the company's ongoing regulatory compliance efforts[5] - The filing reflects the company's commitment to transparency and investor relations[5] Company Information - The press release was dated June 30, 2022, indicating ongoing developments in the company's product pipeline[6] - The document confirms the company's principal executive office is located in Hoersholm, Denmark[1] - The company is incorporated by reference in its registration statements on Form S8 and Form F-3[5]